0001209191-16-110089.txt : 20160322
0001209191-16-110089.hdr.sgml : 20160322
20160322180131
ACCESSION NUMBER: 0001209191-16-110089
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160322
FILED AS OF DATE: 20160322
DATE AS OF CHANGE: 20160322
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Corvus Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001626971
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464670809
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1214
BUSINESS ADDRESS:
STREET 1: 863 MITTEN ROAD
STREET 2: SUITE 102
CITY: BURLINGAME
STATE: CA
ZIP: 94010
BUSINESS PHONE: (650) 900-4520
MAIL ADDRESS:
STREET 1: 863 MITTEN ROAD
STREET 2: SUITE 102
CITY: BURLINGAME
STATE: CA
ZIP: 94010
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novo A/S
CENTRAL INDEX KEY: 0001388325
STATE OF INCORPORATION: G7
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37719
FILM NUMBER: 161521946
BUSINESS ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
BUSINESS PHONE: 45 8824 8824
MAIL ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2016-03-22
0
0001626971
Corvus Pharmaceuticals, Inc.
CRVS
0001388325
Novo A/S
TUBORG HAVNEVEJ 19
HELLERUP
G7
2900
DENMARK
0
0
1
0
Series A Preferred Stock
Common Stock
2130492
D
Series B Preferred Stock
Common Stock
356888
D
The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") has no expiration date and is convertible at any time at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock will automatically convert on a one-for-one basis for no additional consideration into common stock.
Novo A/S is a Danish limited liability company. The board of directors of Novo A/S (the "Novo Board"), currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared investment and voting control over the securities of the Issuer held by Novo A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.
/s/ Thomas Dyrberg, Chief Executive Officer, Novo A/S
2016-03-22